Akèy › Leukemi
Etid klinik pou Leukemi ap rekrite nan Etazini
102 etid pou Leukemi ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX28 etid
- Boston, MA25 etid
- New York City, NY19 etid
- Los Angeles, CA16 etid
- Chicago, IL16 etid
- Durham, NC13 etid
- Baldwin Park, CA12 etid
- Columbus, OH12 etid
- Nashville, TN12 etid
- Philadelphia, PA12 etid
- Seattle, WA11 etid
- Milwaukee, WI11 etid
- Birmingham, AL10 etid
- Atlanta, GA10 etid
- Aurora, CO10 etid
- Mountain View, CA9 etid
- Cincinnati, OH9 etid
- Edison, NJ9 etid
- Miami, FL9 etid
- Portland, OR8 etid
- Dallas, TX8 etid
- New Haven, CT8 etid
- Queens, NY8 etid
- Buffalo, NY7 etid
- Tampa, FL7 etid
- Denver, CO7 etid
- Clifton, NJ7 etid
- Orange, CA7 etid
- Washington, DC7 etid
- Omaha, NE6 etid
- Cedar Rapids, IA6 etid
- Baltimore, MD5 etid
- Ann Arbor, MI5 etid
- Charlottesville, VA5 etid
- Rochester, MN5 etid
- Cleveland, OH5 etid
- Charlotte, NC5 etid
- Memphis, TN5 etid
- San Diego, CA5 etid
- Jacksonville, FL4 etid
Pa eta
- Alabama10 etid
- Arizona7 etid
- Colorado15 etid
- Connecticut11 etid
- Florid17 etid
- Georgia12 etid
- Illinois17 etid
- Indiana4 etid
- Iowa7 etid
- Kalifòni28 etid
- Kansas5 etid
- Kentucky6 etid
- Lwizyàn3 etid
- Main3 etid
- Maryland11 etid
- Massachusetts28 etid
- Michigan8 etid
- Minnesota9 etid
- Missouri6 etid
- Nebraska6 etid
- New Jersey15 etid
- New Mexico3 etid
- New York26 etid
- North Carolina20 etid
- Ohio26 etid
- Oklahoma4 etid
- Oregon9 etid
- Pennsylvania15 etid
- Rhode Island4 etid
- South Carolina6 etid
- Tennessee14 etid
- Texas31 etid
- Utah4 etid
- Vermont4 etid
- Virginia7 etid
- Washington11 etid
- Wisconsin13 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Sep 28, 2026 · NCT00923507Rutgers University Study of the Genetics of Blood Cancers
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 110 · Tout sèks · Mizajou Sep 25, 2026 · NCT07714044Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
Laj 18 a 71 · Tout sèks · Mizajou Sep 23, 2026 · NCT07504458Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
Ap rekriteFaz 2
Laj 1 a 25 · Tout sèks · Mizajou Sep 23, 2026 · NCT05645718Natural History Study of GATA2 Deficiency and Related Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 22, 2026 · NCT01905826Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Ap rekriteFaz 1
Jiska laj 75 · Tout sèks · Mizajou Sep 16, 2026 · NCT06345027A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Ap rekriteFaz 1/2
30 Days · Tout sèks · Mizajou Sep 16, 2026 · NCT04065399Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06824168A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
Ap rekriteFaz 1
Jiska laj 25 · Tout sèks · Mizajou Sep 15, 2026 · NCT06810583(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06229912Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06907797Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Ap rekriteFaz 3
Laj 18 a 18 · Tout sèks · Mizajou Sep 8, 2026 · NCT07509151Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Ap rekriteFaz 2
Laj 1 a 18 · Tout sèks · Mizajou Sep 2, 2026 · NCT07354074Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07249346Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Ap rekriteFaz 1
Laj 1 a 25 · Tout sèks · Mizajou Sep 1, 2026 · NCT06408194First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT07586618Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 5 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT05237986CIML NK Cells With Venetoclax for AML
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT06152809Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07284433Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
Ap rekriteFaz 1
Laj 18 a 90 · Tout sèks · Mizajou Aug 26, 2026 · NCT07439211Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Ap rekriteFaz 1
18 Months – 39 Years · Tout sèks · Mizajou Aug 21, 2026 · NCT07573111Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07007312AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06137118Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.